TAI · 6446.TW
PharmaEssentia Corporation
NT$1,190.00-NT$50.00 (-4.03%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
Loading market information…
TWO · 3218.TWO · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Universal Vision Biotechnology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 19.57% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Universal Vision Biotechnology Co., Ltd.’s forward annual dividend is NT$7.75 per share, paid annual. The forward yield is 5.98% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Universal Vision Biotechnology Co., Ltd.’s next earnings report is currently expected on Nov 18, 2026, with estimated earnings per share of NT$2.95. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Universal Vision Biotechnology Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Universal Vision Biotechnology Co., Ltd., established in 1992 and based in Taipei, Taiwan, manages a network of eye care clinics across both Taiwan and China. The company delivers a comprehensive range of ophthalmic services, encompassing advanced surgical interventions and treatments for various ocular conditions. Its surgical specialties include laser vision correction for common refractive errors such as myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related vision decline). They also perform intraocular lens procedures for presbyopia and cataracts, employing advanced techniques like phacoemulsification and femtosecond laser surgery. Beyond surgical solutions, Universal Vision addresses a wide spectrum of eye health concerns, offering services for myopia control, dry eye syndrome, retinal detachment, macular degeneration, strabismus (crossed eyes), amblyopia (lazy eye), and numerous other ophthalmic ailments. The company further provides a diverse array of vision products and optical aids, including various eyeglass frames, specialized multifocal and progressive lenses for myopia and presbyopia, sunglasses, orthokeratology, rigid gas permeable lenses, and both conventional and colored contact lenses. Nutritional eye supplements are also available. Additional offerings include oculoplastic and micro cosmetic eye surgery, alongside bespoke aesthetic medicine consultations. Furthermore, Universal Vision engages in optometric services, hospital administration, technical advisory roles, and the distribution and rental of medical equipment.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:49 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| NT$1.02B-6.52% vs estimate |
| Q1 2025 | May 14, 2025 | NT$4.27+17.31% vs estimate | NT$1.12B-1.13% vs estimate |
|---|
| Q4 2024 | Mar 6, 2025 | NT$2.80-9.39% vs estimate | NT$1.04B-9.66% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | NT$2.87-17.77% vs estimate | NT$1.08B+4.28% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$1,190.00-NT$50.00 (-4.03%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
NT$159.00-NT$2.50 (-1.55%)
Lin BioScience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.19% below the high.
NT$39.05-NT$1.75 (-4.29%)
Pell Bio-Med Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 97.38% below the high.
NT$379.00-NT$13.00 (-3.32%)
Bora Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 41.78% below the high.
NT$167.50-NT$5.00 (-2.9%)
Lotus Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 54.67% below the high.
NT$419.00-NT$3.50 (-0.83%)
Pegavision Corp.’s quoted price sits in the upper half of its reported 52-week range, 4.12% below the high.
NT$45.80-NT$1.20 (-2.55%)
Oneness Biotech Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 40.29% below the high.
NT$132.50-NT$5.00 (-3.64%)
Handa Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.52% below the high.
